Compare Agnico Eagle Mines Ltd (AEM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Eli Lilly And Co — how do they compare? Agnico Eagle Mines Ltd trades at $144.34 (market cap $75.10B), while Eli Lilly And Co trades at $1,223.04 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 14.6× Agnico Eagle Mines Ltd's market cap, and Agnico Eagle Mines Ltd pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| AEM | LLY | |
|---|---|---|
Market Cap | $75.10B | $1.10T |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $1.24K |
52-Week Low | $116.14 | $625.65 |
Enterprise Value | $72.30B | $1.14T |
Dividend Yield | 1.2% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.
The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
